Quercetin- and rutin-based nano-formulations for cancer treatment: A systematic review of improved efficacy and molecular mechanisms

• Published in: Phytomedicine (Stuttgart) 2022-03, Vol.97, p.153909-153909, Article 153909
• Main Authors: Ghanbari-Movahed, Maryam, Mondal, Arijit, Farzaei, Mohammad Hosein, Bishayee, Anupam
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents; Cancer; Flavonoids; Humans; Nano-formulation; Natural products; Neoplasms - drug therapy; Quercetin; Quercetin - pharmacology; Rutin; Rutin - pharmacology; Targeted therapy
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2021.153909

Natural products, with incredible chemical diversity, have been widely studied for their antitumor potential. Quercetin (QU) and quercetin glycoside (rutin), both polyphenolic flavonoids, stick out amongst the natural products, through various studies. Rutin (RU) and its aglycone (QU) have various biological properties that include antioxidant, anti-inflammatory, and anticarcinogenic activities. However, several side effects have restricted the efficacy of these polyphenolic flavonoids, which makes it necessary to use new strategies involving low and pharmacological doses of QU and RU, either alone or in combination with other anticancer drugs. The aim of this study is to present a comprehensive and critical evaluation of the anticancer ability of different nano-formulations of RU and QU for improved treatment of various malignancies. Studies were recognized via systematic searches of ScienceDirect, PubMed, and Scopus databases. Eligibility checks were conducted based upon predefined selection criteria. Ninety articles were included in this study. There was conclusive evidence for the association between anticancer activity and treatment with RU or QU. Furthermore, studies indicated that nano-formulations of RU and QU have greater anticancer activities in comparison to either agent alone, which leads to increased efficiency for treating cancer. The results of this systematic review demonstrate the anticancer activities of nano-formulations of RU and QU and their molecular mechanisms through preclinical studies. This paper also attempts to contribute to further research by addressing the current limitations/challenges and proposing additional studies to realize the full potential of RU- and QU-based formulations for cancer treatment. [Display omitted]